Troutman Pepper Hamilton Sanders LLP issued the following announcement on Mar. 2.
Troutman Pepper client Center for Breakthrough Medicines (CBM) has struck a landmark collaboration agreement with the University of Pennsylvania’s Gene Therapy Program (GTP) that combines Penn’s knowledge and expertise in the development of gene therapies with CBM’s manufacturing capacity and singular focus on advanced therapies.
This CBM partnership with GTP is focused on moving therapeutics safely and rapidly from concept to clinic by connecting certain of Penn’s established gene therapy platforms with CBM’s manufacturing and analytical capacity. The combination will allow small biotech firms, universities, and large pharmaceutical companies to advance gene therapies from discovery to First-In-Human (FIH) studies with the potential for less risk and expense. Read CBM’s press release about the potentially life-saving partnership with GTP.
The Troutman Pepper team advising CBM in the collaboration agreement was led by Partner Rachael Bushey and included Associates Allison Nicklin and Neil Doogan. The firm recently counseled CBM in a $350 million investment from SK Inc.
“Rachel, Allison and the entire Troutman Pepper team were instrumental in expertly guiding Center for Breakthrough Medicines through this complex and foundational alliance with Dr. Wilson, Penn and GTP,” said Audrey Greenberg, Founder, Center for Breakthrough Medicines. “Troutman Pepper’s Life Science practice is among the most sophisticated and networked in the country, in particular in Philadelphia’s Cellicon Valley, which is why CBM has relied on them since its inception as its go-to law firm.”
CBM offers fully integrated, bench to bedside, pre-clinical through commercial manufacturing capabilities including, process development, plasmid DNA, viral vector manufacturing, cell banking, cell processing, and a full suite of complimentary testing and analytic capabilities.
Original source can be found here.